Organization | Turkish Society of Hematology

Turkish Society of Hematology Report issue

Academic/Hospital Phase 3 Phase 4

Organization Overview

First Clinical Trial

2006

NCT00934154

First Marketed Drug

None

First NDA Approval

None

Last Known Activity

2011

Timeline

NOW

Now

Alternative names

Turkish Society of Hematology Myeloma Study Group

Active Ingredients

Drugs in Phase 4 Trials (1)

atorvastatin (lipitor) (1 trial)

Drugs in Phase 3 Trials (3)

melphalan (alkeran) (1 trial)

prednisone (meticorten) (1 trial)

thalidomide (Thalomid) (1 trial)

Drugs in Other Trials (6)

antihemophilic factor viii human (Hemofil M) (1 trial)

azathioprine (imuran) (1 trial)

coagulation factor viia (recombinant) (NovoSevenRT) (1 trial)

cyclosporine (sandimmune) (1 trial)

desmopressin (ddavp) (1 trial)

rituximab (rituxan) (1 trial)

Indications

Experimental Indications (Clinical Trials, Phases 1-4)

Multiple Myeloma (Phase 3)

Neoplasms, Plasma Cell (Phase 3)

Overview

Highest Phase: Phase 4
# of Trials: 3
# of Trial APIs: 10